Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT06915753 is registered in ClinicalTrials.gov with Tyra Biosciences, Inc as lead sponsor.

NCT NCT06915753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06915753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Lead sponsor
Tyra Biosciences, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
April 24, 2025
Completion date
September 30, 2028
Enrollment
125 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, fgf19 gene amplification, fgf19 gene overexpression, fgfr gene alterations, fgfr gene amplification, fgfr4 gene fusions, fgfr4 gene mutation, locally advanced unresectable hepatocellular carcinoma, metastatic hepatocellular carcinoma, solid tumor, adult, solid tumors